These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands. Chen Y; Shi Y; Cheng H; An YQ; Gao GF IUBMB Life; 2009 Jun; 61(6):579-90. PubMed ID: 19472182 [TBL] [Abstract][Full Text] [Related]
5. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Renauld JC Nat Rev Immunol; 2003 Aug; 3(8):667-76. PubMed ID: 12974481 [TBL] [Abstract][Full Text] [Related]
6. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Sarkar S; Tesmer LA; Hindnavis V; Endres JL; Fox DA Arthritis Rheum; 2007 Jan; 56(1):89-100. PubMed ID: 17195211 [TBL] [Abstract][Full Text] [Related]
8. Emerging therapeutics for rheumatoid arthritis. Bingham CO Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634 [TBL] [Abstract][Full Text] [Related]
9. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375 [TBL] [Abstract][Full Text] [Related]
10. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Vermeire S; Van Assche G; Rutgeerts P Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190 [TBL] [Abstract][Full Text] [Related]
11. Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells. Hirata N; Yanagawa Y; Ebihara T; Seya T; Uematsu S; Akira S; Hayashi F; Iwabuchi K; Onoé K Mol Immunol; 2008 May; 45(10):2734-42. PubMed ID: 18372043 [TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976 [TBL] [Abstract][Full Text] [Related]
13. Naive human T-cells become non-responsive towards anti-TNFalpha (infliximab) treatment in vitro if co-stimulated through CD28. Gunnlaugsdottir B; Skaftadottir I; Ludviksson BR Scand J Immunol; 2008 Dec; 68(6):624-34. PubMed ID: 19000096 [TBL] [Abstract][Full Text] [Related]
14. Intracellular JNK, p38 MAPK and NF-kappaB regulate IL-25 induced release of cytokines and chemokines from costimulated T helper lymphocytes. Wong CK; Li PW; Lam CW Immunol Lett; 2007 Oct; 112(2):82-91. PubMed ID: 17719653 [TBL] [Abstract][Full Text] [Related]
15. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Peggs KS; Quezada SA; Allison JP Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925 [TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288 [TBL] [Abstract][Full Text] [Related]
17. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510 [TBL] [Abstract][Full Text] [Related]
18. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Siebler J; Wirtz S; Weigmann B; Atreya I; Schmitt E; Kreft A; Galle PR; Neurath MF Gastroenterology; 2007 Jan; 132(1):358-71. PubMed ID: 17241885 [TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Ghosh TK; Mickelson DJ; Fink J; Solberg JC; Inglefield JR; Hook D; Gupta SK; Gibson S; Alkan SS Cell Immunol; 2006 Sep; 243(1):48-57. PubMed ID: 17250816 [TBL] [Abstract][Full Text] [Related]